Literature DB >> 16470403

Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.

Ainhoa Bilbao1, Andrea Cippitelli, Ana Belén Martín, Noelia Granado, Oscar Ortiz, Erwan Bezard, Jiang-Fan Chen, Miguel Navarro, Fernando Rodríguez de Fonseca, R Moratalla.   

Abstract

RATIONALE: Caffeine and other methylxanthines induce behavioral activation and anxiety responses in mice via antagonist action at A2A adenosine receptors. When combined with the opioid antagonist naloxone, methylxanthines produce a characteristic quasi-morphine withdrawal syndrome (QMWS) in opiate-naive animals.
OBJECTIVES: The aim of this study was to establish the role of A2A receptors in the quasi-morphine withdrawal syndrome induced by co-administration of caffeine and naloxone and in the behavioral effects of caffeine.
METHODS: We have used A2A receptor knockout (A(2A)R(-/-)) mice in comparison with their wild-type and heterozygous littermates to measure locomotor activity in the open field and withdrawal symptoms induced by caffeine and naloxone. Naïve wild-type and knockout mice were also examined for enkephalin and dynorphin mRNA expression by in situ hybridization and for mu-opiate receptor by ligand binding autoradiography to check for possible opiate receptor changes induced by A2A receptor inactivation.
RESULTS: Caffeine increases locomotion and anxiety in wild-type animals, but it has no psychomotor effects in A(2A)R(-/-) mice. Co-administration of caffeine (20 mg/kg) and naloxone (2 mg/kg) resulted in a severe quasi-morphine withdrawal syndrome in wild-type mice that was almost completely abolished in A(2A)R(-/-) mice. Heterozygous animals exhibited a 40% reduction in withdrawal symptoms, suggesting that there is no genetic/developmental compensation for the inactivation of one of the A(2A)R alleles. A(2A)R(-/-) and wild-type mice have similar levels of striatal mu-opioid receptors, thus the effect is not due to altered opioid receptor expression.
CONCLUSIONS: Our results demonstrate that A2A receptors are required for the induction of quasi-morphine withdrawal syndrome by co-administration of caffeine and naloxone and implicate striatal A2A receptors and mu-opiate receptors in tonic inhibition of motor activity in the striatum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470403     DOI: 10.1007/s00213-005-0284-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

Review 1.  Central adenosine A(2A) receptors: an overview.

Authors:  J L Moreau; G Huber
Journal:  Brain Res Brain Res Rev       Date:  1999-12

2.  Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat.

Authors:  N Rebola; P M Canas; C R Oliveira; R A Cunha
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors.

Authors:  B Johansson; V Georgiev; B B Fredholm
Journal:  Neuroscience       Date:  1997-10       Impact factor: 3.590

4.  Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits.

Authors:  M Yano; H Steiner
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

5.  Adenosine receptors are involved in the control of acute naloxone-precipitated withdrawal: in vitro evidence.

Authors:  A Capasso
Journal:  Life Sci       Date:  2000       Impact factor: 5.037

Review 6.  Functions of neuronal adenosine receptors.

Authors:  H L Haas; O Selbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

7.  Long-term effect of in vitro culture of mouse embryos with serum on mRNA expression of imprinting genes, development, and behavior.

Authors:  Raúl Fernández-Gonzalez; Pedro Moreira; Ainhoa Bilbao; Adela Jiménez; Miriam Pérez-Crespo; Miguel Angel Ramírez; Fernando Rodríguez De Fonseca; Belén Pintado; Alfonso Gutiérrez-Adán
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

8.  Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines.

Authors:  H O Collier; N J Cuthbert; D L Francis
Journal:  Fed Proc       Date:  1981-04

Review 9.  Involvement of basal ganglia transmitter systems in movement initiation.

Authors:  W Hauber
Journal:  Prog Neurobiol       Date:  1998-12       Impact factor: 11.685

10.  Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats.

Authors:  Cristina Grande; Hongwen Zhu; Ana B Martin; MoonSook Lee; Oscar Ortiz; Noboru Hiroi; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382

View more
  5 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 3.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

4.  Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and Anxiety.

Authors:  Joana E Coelho; Pedro Alves; Paula M Canas; Jorge S Valadas; Tatiana Shmidt; Vânia L Batalha; Diana G Ferreira; Joaquim A Ribeiro; Michael Bader; Rodrigo A Cunha; Frederico Simões do Couto; Luísa V Lopes
Journal:  Front Psychiatry       Date:  2014-06-13       Impact factor: 4.157

Review 5.  Adenosine A2AReceptors in Substance Use Disorders: A Focus on Cocaine.

Authors:  Karolina Wydra; Dawid Gawliński; Kinga Gawlińska; Małgorzata Frankowska; Dasiel O Borroto-Escuela; Kjell Fuxe; Małgorzata Filip
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.